DBV Technologies S.A. (NASDAQ:DBVT) Receives $35.38 Average Target Price from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received an average rating of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $35.3750.

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. HC Wainwright set a $40.00 target price on DBV Technologies in a research note on Thursday, December 18th. Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a research note on Wednesday, December 17th. Finally, Citizens Jmp lifted their price objective on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th.

DBV Technologies Price Performance

NASDAQ DBVT opened at $20.90 on Friday. The business’s fifty day moving average is $20.26 and its 200-day moving average is $14.83. The stock has a market capitalization of $839.34 million, a price-to-earnings ratio of -4.04 and a beta of -0.98. DBV Technologies has a one year low of $3.82 and a one year high of $26.18.

Insider Activity

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the sale, the insider directly owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This represents a 15.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 3,369,627 shares of company stock valued at $15,489,908 over the last 90 days. Insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

A number of large investors have recently made changes to their positions in the stock. Allworth Financial LP purchased a new stake in DBV Technologies during the 4th quarter worth about $32,000. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies in the third quarter worth about $34,000. GAMMA Investing LLC boosted its position in shares of DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the period. Two Sigma Investments LP purchased a new position in DBV Technologies during the third quarter valued at approximately $167,000. Finally, Citadel Advisors LLC purchased a new stake in DBV Technologies in the 3rd quarter worth approximately $220,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.